WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common
WALTHAM, Mass. --(BUSINESS WIRE)--May 30, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased Response Rate and Durable Benefit with Longer-Term Follow Up Conference Call Scheduled for 8 a.m. ET on Thursday, May 17 WALTHAM, Mass.
Patient Enrollment in FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine Completed Ahead of Schedule; On Track for Top-Line Results in the First Half of 2019 Encouraging Data Reported from FORWARD II Assessment of Mirvetuximab with Keytruda ® ; Additional Combination Data to be Presented in 2018,
WALTHAM, Mass. --(BUSINESS WIRE)--May 2, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43 rd Annual Health Care Conference .
FORWARD I trial has completed full enrolloment; top-line results expected in the first half of 2019 WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 26, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee , Ph.D. has been appointed Executive Vice President and Chief Business Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 20, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in